Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

GLS Said

Gold Seeker Wednesday, 10/29/14 07:57:29 PM
Re: guardiangel post# 25873
Post # of 25879
It was an attachment to the 8k for the uni agreement. Look it up.



We did look it up I guess you didn't see my post that shows the attaxhment you were referring to was dated on June 6, 2013..Up to June 6 ADI was a wholly owned subsidiary.. 5 days later on June 11, 2013 Mac filed the 8-K stating that ADI was a Division.. SEC Filings are the facts. I glad you now agree that ADI is a Division, unless you think that the 8-K is not a factual document...Wolf Pack

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=107650417

guardiangel Wednesday, 10/29/14 12:51:32 PM
Re: dcspka post# 25872
Post # of 25879
DC We will post what the skeptic stated about ADI being a wholly subsidiary of Radient..As you will see, the agreement was June 6m 2013, showing ADI as a Wholly owned subsidiary then 5 days later,ADI became a division..As you and we know..Radient can change a Wholly owned subsidiary to division at a"whim"..Proof shows that we are a Division from the 8-K..

http://www.sec.gov/Archives/edgar/data/838879/000121390013003193/f8k061113a1ex10i_radient.htm

This License Agreement (the “Agreement”), which shall be effective as of June 6th , 2013, is by and between Uni Pharma Co., Ltd., a Taipei, Taiwan limited liability company (“UNI”) and Radient Pharmaceuticals Corporation (including its subsidiary AMDL Diagnostics Inc.) a Delaware incorporated United States company (“RXPC”).

The 8=K was dated June 18, 2013...

Section 1 - Registrant’s Business and Operations

Item 1.01 - Entry into Material Definitive Agreements

We filed a Current Report on Form 8-K on June 11, 2013 to disclose our entry into a 5-year license agreement between AMDL Diagnostics, Inc. (“ADI”), a division within our company, and Uni Pharma Co., Ltd. a Taipei Taiwan limited liability company (“UNI”) that provides UNI with a 5-year exclusive license (subject to automatic renewal for an additional 5 years) to RXPC’s Onko-Sure® (formerly called DR-70 cancer blood test kits (the “Tests”), procedures, analyses, data, know how, manufacturing, manufacturing processes, components, trademarks and intellectual property.